Pelthos Therapeutics Inc. (PTHS)
| Market Cap | 77.56M -8.5% |
| Revenue (ttm) | 43.30M |
| Net Income | -86.39M |
| EPS | -26.36 |
| Shares Out | 3.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,687 |
| Open | 20.16 |
| Previous Close | 20.15 |
| Day's Range | 19.81 - 20.46 |
| 52-Week Range | 18.19 - 37.50 |
| Beta | 3.11 |
| Analysts | Strong Buy |
| Price Target | 51.71 (+155.23%) |
| Est. Earnings | Nov 12, 2026 |
About PTHS
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestati... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for PTHS stock is "Strong Buy." The 12-month stock price target is $51.71, which is an increase of 155.23% from the latest price.
News
Pelthos Therapeutics price target lowered to $40 from $50 at Lake Street
Lake Street lowered the firm’s price target on Pelthos Therapeutics (PTHS) to $40 from $50 and keeps a Buy rating on the shares. The firm is reducing Zelsuvmi estimates for…
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
Company secures new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives Pelthos gains enhanced commercial coverage through a regional commercial h...
Pelthos Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and proceeded with three proposals: board elections, auditor ratification, and approval of the 2026 equity incentive plan. All proposals passed with the requisite votes, and final results will be filed in a Form 8-K.
Pelthos Therapeutics Proxy statement: Proxy filing
Pelthos Therapeutics filed a proxy statement on August 18, 2026, providing details for shareholder voting and corporate governance matters.
Pelthos Therapeutics Proxy statement: Proxy filing
Pelthos Therapeutics filed a proxy statement on August 18, 2026, providing details for shareholder voting and corporate governance matters.
Pelthos Therapeutics price target lowered to $45 from $75 at Alliance Global
Alliance Global lowered the firm’s price target on Pelthos Therapeutics (PTHS) to $45 from $75 and keeps a Buy rating on the shares after the company released their Q2 results…
Pelthos Therapeutics price target lowered to $64 from $66 at Oppenheimer
Oppenheimer analyst Jeff Jones lowered the firm’s price target on Pelthos Therapeutics (PTHS) to $64 from $66 and keeps an Outperform rating on the shares following quarterly results. The firm…
Pelthos Therapeutics Earnings Call Transcript: Q2 2026
Q2 revenue rose 45% QoQ to $15.4M as ZELSUVMI prescribed units grew 48%. Cash was $24.2M, and launches of XEPI and XEGLYZE are targeted for 2027.
Pelthos Therapeutics Earnings release: Q2 2026
Pelthos Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Pelthos Therapeutics Quarterly report: Q2 2026
Pelthos Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Pelthos Therapeutics Slides: Corporate presentation
Pelthos Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026
Pelthos Therapeutics Proxy statement: Proxy filing
Pelthos Therapeutics filed a proxy statement on August 7, 2026, providing details for shareholder voting and corporate governance matters.
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet pati...
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders v...
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet pati...
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patie...
Pelthos Therapeutics price target raised to $66 from $62 at Oppenheimer
Oppenheimer analyst Jeff Jones raised the firm’s price target on Pelthos Therapeutics (PTHS) to $66 from $62 and keeps an Outperform rating on the shares after the company reported results…
Pelthos Therapeutics reports Q1 EPS ($3.58), consensus ($3.09)
Reports Q1 revenue $10.91M, consensus $10.44M. Scott Plesha, CEO of Pelthos, stated, “In the first quarter of 2026, we continued to build momentum for ZELSUVMI, driven by the expansion of…
Pelthos Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth and prescription gains for ZELSUVMI, supported by sales force expansion and a major PBM contract. Net loss narrowed, working capital improved, and launches for Xepi and Xeglyze are on track for 2027. Medicaid coverage for ZELSUVMI reached 99%.
Pelthos Therapeutics Earnings release: Q1 2026
Pelthos Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Pelthos Therapeutics Quarterly report: Q1 2026
Pelthos Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 uniq...
Pelthos Therapeutics Slides: Corporate presentation
Pelthos Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patie...